EGFR and esophageal squamous cell carcinoma: EGFR is expressed in 33.3% of esophageal squamous cell carcinomas (ESCCs), Lapatinib can have a significant therapeutic effect against EGFR-expressing ESCC by inhibiting the growth of ESCC cells and augmenting Herceptin- and Cetuximab-mediated ADCC [18].